pep-cmv
Vaccineexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2014 (NCT01854099)
Timeline
Indications
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pep-cmv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06639607 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | National Cancer Institute (NCI), Washington University in St. Louis |
| NCT06132438 | Phase 1 | Nov 30, 2023 | University of New South Wales |
| NCT05096481 | Phase 2 | Mar 31, 2022 | Duke University, Ohio State University |
| NCT03299309 | Phase 1 | Jun 29, 2018 | Annias Immunotherapeutics, Inc., Duke University, Pediatric Brain Tumor Foundation |
| NCT02864368 | Phase 1 | Dec 1, 2016 | Annias Immunotherapeutics, Inc., Duke University, National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01854099 | Phase 1 | Jan 1, 2014 | American Brain Tumor Association, University of Florida |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 3 | 2 | 2 | 2016 |
| Annias Immunotherapeutics, Inc. | For profit | 2 | 0 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2016 |
| American Brain Tumor Association | Academic/Hospital | 1 | 0 | 1 | 2014 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2016 |
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Pediatric Brain Tumor Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of New South Wales | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2025 |
10 organizations
Page 1 / 1